Photo from wikipedia
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better… Click to show full abstract
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways. See related article by Karasinska et al., p. 135
Keywords:
metabolic subtyping;
novel personalized;
cancer;
personalized therapies;
subtyping novel;
pancreatic cancer
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!